Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Future 'on track' to meet FY expectations, makes 'good progress' on strategy

(Sharecast News) - Publishing company Future said on Thursday that it remains on track to achieve FY25 market expectations after making "good progress" executing on its strategy. Future said its B2C unit saw US advertising return to growth, up 5% year-on-year in Q3, while its UK advertising arm reported an 8% year-on-year decline.

Magazine revenues "remained resilient" and showed an improvement on the previous year's rate of decline, while eCommerce affiliate revenues declined in Q3, as expected.

The FTSE 250-listed firm also said its B2B's performance was as expected in Q3, showing an improvement on its H1 performance despite the market remaining "mixed", with softness continuing in enterprise technology and offsetting good progress in other verticals.

Chief executive Kevin Li Ying said: "We are pleased with our overall performance in the third quarter, which keeps us on track to deliver on expectations for the full year. We remain mindful of the environment, including ongoing search changes and macroeconomic backdrop.

"As we set out at HY results, our focus is on building the business for tomorrow whilst delivering on today and we look forward to updating on our progress at full year results."

As of 0905 BST, Future shares had shot up 9.55% to 780.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.